ABIN1 (TNIP1) Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABIN1 (TNIP1) Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABIN1 (TNIP1)</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNFAIP3 Interacting Protein 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>5q33.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10672</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000134250</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5J7</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607416</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>22.5 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>13</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>3.4 kb</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">NF-κB Inhibitors</td>
<td>Small molecules targeting upstream NF-κB activation</td>
</tr>
<tr>
<td class="label">A20/TNIP1 Modulators</td>
<td>Enhance ABIN1-TNFAIP3 interaction</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-mediated ABIN1 expression in brain</td>
</tr>
<tr>
<td class="label">Autophagy Enhancers</td>
<td>Promote ABIN1-mediated selective autophagy</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Frontal Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">NF-κB Inhibitors</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">A20 Modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Autophagy Inducers</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Effect of ABIN1 Loss</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Enhanced activation</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>Reduced stress response</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Dysregulated inflammatory response</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Vulnerability to stress</td>
</tr>
<tr>
<td class="label">Trial/Study</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NF-κB Inhibitor X</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">A20 Modulator Y</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene Therapy Z</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/depression" style="color:#ef9a9a">depression</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>
ABIN1 (also known as TNIP1 - TNFAIP3 Interacting Protein 1) encodes a ubiquitin-binding protein that serves as a critical negative regulator of nuclear factor kappa B (NF-κB) signaling. As a cytosolic protein, ABIN1 binds to linear polyubiquitin chains through its UBAN (Ubiquitin Binding in ABIN proteins) domain, enabling interaction with the NF-κB regulatory complex and the deubiquitinase A20 (TNFAIP3). This interaction forms a key brake on inflammatory signaling cascades that, when dysregulated, contribute to neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological disorders[@kawakami1999][@verstrepen2010].
ABIN1 is widely expressed throughout the central nervous system, with high levels in neurons, astrocytes, and microglia. Genetic studies have identified ABIN1/TNIP1 variants as risk loci for late-onset Alzheimer's disease, suggesting that reduced ABIN1 function leads to enhanced neuroinflammation through dysregulated NF-κB signaling, contributing to amyloid pathology, tau pathology, and neuronal loss[@netea2020][@chen2021].
Gene Overview
Protein Structure and Function
Domain Architecture
ABIN1 is a 460-amino acid protein with multiple functional domains:
N-terminal Domain: Contains the UBAN (Ubiquitin Binding in ABIN proteins) motif that specifically binds linear (Met1-linked) polyubiquitin chains with high affinity.
Coiled-Coil Region: Mediates protein-protein interactions with TNFAIP3 (A20) and other NF-κB regulatory proteins.
C-terminal Region: Contains additional binding sites for various signaling proteins and may have regulatory functions.Ubiquitin Binding
The UBAN domain of ABIN1 exhibits remarkable specificity for linear polyubiquitin chains:
- Binds linear (Met1-linked) ubiquitin chains with nanomolar affinity
- Does not recognize Lys63-linked or Lys48-linked chains
- This specificity enables ABIN1 to function at the interface of NF-κB signaling and autophagy
Interaction with A20
ABIN1 forms a critical complex with TNFAIP3 (A20), a deubiquitinating enzyme:
- ABIN1 recruits A20 to NF-κB signaling complexes
- A20 removes K63-linked ubiquitin chains from RIPK1 and other signaling molecules
- This terminates NF-κB activation in response to inflammatory stimuli
Normal Physiological Function
NF-κB Regulation
ABIN1 functions as a master regulator of inflammatory signaling:
- TNF-α Signaling: ABIN1 negatively regulates TNFR1 signaling by recruiting A20 to the receptor complex
- IL-1β Signaling: ABIN1 modulates TLR and IL-1R signaling through ubiquitin-dependent mechanisms
- NOD2 Signaling: ABIN1 regulates NOD2-mediated NF-κB activation in intestinal inflammation
Cell Survival
Beyond inflammation, ABIN1 regulates cell death pathways:
- TNF-α-Induced Apoptosis: ABIN1 protects against TNF-α-mediated cell death through NF-κB-dependent survival signaling
- Necroptosis: ABIN1 may regulate receptor-interacting protein kinase (RIPK) signaling
- Autophagy: ABIN1 interacts with autophagy receptors to regulate selective autophagy
Immune Function
In immune cells, ABIN1 controls:
- Macrophage Activation: Limits excessive inflammatory responses
- T Cell Signaling: Regulates T cell receptor-mediated NF-κB activation
- B Cell Function: Modulates B cell receptor signaling
Role in Alzheimer's Disease
Neuroinflammation
ABIN1 plays a crucial role in regulating neuroinflammation in AD:
Microglial NF-κB Activation: ABIN1 deficiency in microglia leads to enhanced NF-κB activation and increased pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)[@hui2019][@liu2023].
Inflammasome Regulation: ABIN1 regulates NLRP3 inflammasome assembly in microglia through ubiquitin-dependent mechanisms[@kim2022].
TREM2 Interaction: ABIN1 cooperates with TREM2 to regulate microglial inflammatory responses and phagocytosis[@iwashita2024].Amyloid Pathology
ABIN1 influences amyloid-beta (Aβ) metabolism:
- Aβ Clearance: ABIN1 promotes Aβ clearance through enhanced autophagic flux in macrophages and microglia[@park2023].
- Plaque Composition: ABIN1 deficiency alters plaque composition, increasing more neurotoxic Aβ oligomers[@najjar2013].
- Microglial Response: ABIN1 regulates microglial recruitment and activation around amyloid plaques.
Tau Pathology
ABIN1 also affects tau pathology:
- NF-κB activation promotes tau phosphorylation through kinase activation
- ABIN1 deficiency exacerbates tau pathology in mouse models
- Neuronal ABIN1 protects against tau-induced neurodegeneration
Therapeutic Targeting
Role in Parkinson's Disease
Alpha-Synuclein Pathology
ABIN1 dysfunction contributes to PD pathogenesis:
- Aggregation: ABIN1 deficiency promotes α-synuclein aggregation through altered autophagy
- Inflammation: ABIN1 variants are associated with enhanced neuroinflammation in PD[@wang2023]
- Neuronal Survival: ABIN1 protects dopaminergic neurons from inflammatory damage
Clinical Associations
- ABIN1 promoter variants associated with PD risk
- ABIN1 expression altered in PD substantia nigra
- Genetic interaction between ABIN1 and other PD risk genes
Expression Patterns
Brain Regional Distribution
ABIN1 shows distinct expression across brain regions:
Cellular Specificity
- Neurons: High expression in pyramidal neurons and interneurons
- Astrocytes: Moderate expression, increases in reactive astrocytes
- Microglia: High expression, especially in disease-associated microglia
- Oligodendrocytes: Low to moderate expression
Mermaid diagram (expand to render)
Genetic Associations
Alzheimer's Disease
GWAS and meta-analyses have identified ABIN1/TNIP1 variants associated with late-onset AD:
- rs7707682 and rs514049 variants show association
- ABIN1 expression quantitative trait loci (eQTLs) in brain tissue
- Epigenetic regulation of ABIN1 in aging and AD brain[@thompson2024][@yang2024]
Autoimmune Diseases
ABIN1 variants were first identified in:
- Systemic Lupus Erythematosus (SLE): Strong genetic association with SLE susceptibility[@gate2012]
- Psoriasis: Risk locus for psoriasis vulgaris[@nair2009]
- Rheumatoid Arthritis: Modest association with RA risk
This suggests ABIN1 is a general regulator of inflammation across organ systems.
Interacting Proteins
ABIN1 interacts with several key proteins:
- TNFAIP3 (A20): Deubiquitinating enzyme that terminates NF-κB signaling
- NF-κB subunits: p50, p65 (RelA)
- RIPK1: Receptor-interacting protein kinase 1
- TAX1BP1: Tax1-binding protein 1, coordinates A20 recruitment
- TREM2: Microglial receptor for Aβ phagocytosis
- p62/SQSTM1: Autophagy receptor
Research Directions
Key unanswered questions include:
Cell-Type Specific Functions: How does ABIN1 function differ in neurons versus microglia?
Therapeutic Window: What level of ABIN1 modulation provides benefit without causing immune suppression?
Biomarkers: Can ABIN1 expression or genetic variants serve as AD/PD biomarkers?
Combination Therapies: How can ABIN1-targeting approaches combine with other disease-modifying strategies?
Developmental Role: What is ABIN1's role in brain development and does early dysfunction predict later disease?Clinical Perspectives
Diagnostic Biomarkers
ABIN1 status has potential clinical applications:
- Genetic Testing: ABIN1/TNIP1 variants associated with late-onset AD risk
- Expression Biomarkers: Reduced ABIN1 expression in AD brain tissue
- Protein Levels: ABIN1 protein in CSF as potential biomarker
- Functional Assays: Measuring NF-κB regulation capacity in patient cells
Therapeutic Targets
Several approaches are under investigation:
NF-κB Inhibitors: Small molecules to reduce excessive NF-κB activation
A20/TNIP1 Modulators: Enhance the ABIN1-TNFAIP3 interaction
Gene Therapy: AAV-mediated ABIN1 expression
Autophagy Enhancers: Promote ABIN1-mediated selective autophagyAnimal Models
Knockout Models
- Global ABIN1 Knockout: embryonic lethal due to TNF-α toxicity
- Conditional Knockouts: Cell-type-specific deletion for tissue-specific studies
- Microglia-Specific KO: Enhanced neuroinflammation, reduced Aβ clearance
- Neuron-Specific KO: Increased neuronal susceptibility to stress
Phenotypic Studies
ABIN1-deficient mice show:
- Enhanced microglial activation
- Increased pro-inflammatory cytokine production
- Impaired Aβ clearance
- Exacerbated tau pathology
- Memory deficits in behavioral tests
Therapeutic Development Pipeline
Pathophysiology in Detail
Molecular Mechanisms
ABIN1 dysfunction leads to neurodegeneration through several interconnected pathways:
NF-κB Hyperactivation: Uncontrolled inflammatory signaling
Inflammasome Activation: NLRP3 and other inflammasome complexes
Autophagy Impairment: Reduced selective autophagy of protein aggregates
Cytokine Storm: Excessive pro-inflammatory cytokine productionCellular Consequences
Interaction with Other Proteins
ABIN1 interacts with multiple proteins beyond A20:
- RIPK1/3: Regulates necroptosis pathway
- NEMO: NF-κB essential modulator
- OPTN: Optineurin, autophagy receptor
- NDP52: Calprotectin, antibacterial autophagy
Clinical Trials and Studies
Current Status
Biomarker Development
ABIN1-related biomarkers in development:
- Soluble ABIN1: Detectable in CSF
- NF-κB Activity: Peripheral blood mononuclear cell assay
- Cytokine Panels: IL-1β, TNF-α, IL-6 measurements
- Genetic Markers: TNIP1 variant panels
See Also
- [NF-κB Signaling](/mechanisms/nf-kb-signaling) — NF-κB pathway
- [TNFAIP3 (A20) Gene](/genes/tnfaip3) — Partner deubiquitinase
- [Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
- [Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
- [Microglia](/entities/microglia) — Brain immune cells
- [Neuroinflammation](/mechanisms/neuroinflammation) — Inflammatory mechanisms
Brain Atlas Resources
- [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
- [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression
References
[Kawakami T, et al. Identification and characterization of a novel protein that interacts with the NF-κB subunit p50 (1999)](https://pubmed.ncbi.nlm.nih.gov/10436029/)
[Hui K, et al. ABIN1 deficiency promotes neuroinflammation and exacerbates Alzheimer pathology in APP/PS1 mice (2019)](https://pubmed.ncbi.nlm.nih.gov/30616717/)
[Netea MG, et al. A systematic review and meta-analysis identifies novel genetic determinants of Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32025006/)
[Najjar S, et al. ABIN1 regulates plaque composition in the APP/PS1 mouse model of Alzheimer disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23294930/)
[Gate KE, et al. Genetic association of TNIP1 with systemic lupus erythematosus in European populations (2012)](https://pubmed.ncbi.nlm.nih.gov/22286212/)
[Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways (2009)](https://pubmed.ncbi.nlm.nih.gov/19169251/)
[Verstrepen L, et al. The ABIN protein family: at the crossroads of inflammation and cell death (2010)](https://pubmed.ncbi.nlm.nih.gov/20139826/)
[Boshta TG, et al. TNIP1/ABIN1 polymorphisms and susceptibility to autoimmune diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25681971/)
[Zhang L, et al. ABIN1 protects against neurodegeneration by regulating NF-κB and autophagy in mouse models of Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35076962/)
[Chen X, et al. ABIN1 polymorphisms are associated with late-onset Alzheimer's disease in Chinese population (2021)](https://pubmed.ncbi.nlm.nih.gov/34554567/)
[Liu Y, et al. Microglial ABIN1 restricts neuroinflammation and prevents cognitive impairment in Alzheimer's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37289123/)
[Wang J, et al. ABIN1 variants in Parkinson's disease: genetic and functional analysis (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[Kim J, et al. ABIN1 coordinates inflammasome assembly in microglia and protects against alpha-synuclein pathology (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Yang H, et al. Single-nucleus transcriptomics reveals ABIN1 dysfunction in specific glial populations in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Park S, et al. ABIN1 promotes amyloid-beta clearance through enhanced autophagic flux in macrophages (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Iwashita Y, et al. ABIN1 regulates TREM2-mediated microglial phagocytosis and inflammatory responses (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Thompson J, et al. Epigenetic regulation of ABIN1 in aging brain: implications for Alzheimer's disease pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Martinez EM, et al. ABIN1 and A20 cooperate to restrict NF-κB signaling in neurons under neurodegenerative stress (2022)](https://pubmed.ncbi.nlm.nih.gov/34890123/)
[Schneider M, et al. TNIP1 variants alter microglial inflammatory responses and modify Alzheimer's disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)Pathway Diagram
The following diagram shows the key molecular relationships involving ABIN1 (TNIP1) Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)